Antipodes Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,078
| Closed | -$121K | – | 111 |
|
|
2025
Q1 | $121K | Buy |
+1,078
| New | +$121K | ﹤0.01% | 70 |
|
|
2023
Q2 | – | Sell |
-1,204,538
| Closed | -$99.9M | – | 73 |
|
|
2023
Q1 | $99.9M | Sell |
1,204,538
-112,203
| -9% | -$9.31M | 3.46% | 14 |
|
|
2022
Q4 | $113M | Buy |
1,316,741
+249,941
| +23% | +$21.5M | 4.06% | 7 |
|
|
2022
Q3 | $65.8M | Buy |
+1,066,800
| New | +$65.8M | 2.64% | 15 |
|
|
2020
Q4 | – | Sell |
-355,411
| Closed | -$22.5M | – | 35 |
|
|
2020
Q3 | $22.5M | Sell |
355,411
-542,431
| -60% | -$34.3M | 1.03% | 30 |
|
|
2020
Q2 | $69.1M | Buy |
897,842
+7,475
| +0.8% | +$575K | 3.13% | 13 |
|
|
2020
Q1 | $66.6M | Sell |
890,367
-618,729
| -41% | -$46.3M | 3.48% | 16 |
|
|
2019
Q4 | $98.1M | Sell |
1,509,096
-315,194
| -17% | -$20.5M | 4.42% | 11 |
|
|
2019
Q3 | $116M | Sell |
1,824,290
-49,715
| -3% | -$3.15M | 5.52% | 6 |
|
|
2019
Q2 | $127M | Buy |
1,874,005
+479,034
| +34% | +$32.4M | 5.81% | 7 |
|
|
2019
Q1 | $90.7M | Sell |
1,394,971
-304,953
| -18% | -$19.8M | 4.48% | 11 |
|
|
2018
Q4 | $106M | Sell |
1,699,924
-218,787
| -11% | -$13.7M | 5.25% | 9 |
|
|
2018
Q3 | $148M | Sell |
1,918,711
-159,846
| -8% | -$12.3M | 6.88% | 8 |
|
|
2018
Q2 | $147M | Sell |
2,078,557
-627,295
| -23% | -$44.4M | 7% | 3 |
|
|
2018
Q1 | $204M | Buy |
2,705,852
+909,370
| +51% | +$68.6M | 9.15% | 1 |
|
|
2017
Q4 | $129M | Buy |
1,796,482
+518,890
| +41% | +$37.2M | 7.54% | 4 |
|
|
2017
Q3 | $103M | Buy |
1,277,592
+182,235
| +17% | +$14.8M | 7.6% | 2 |
|
|
2017
Q2 | $77.5M | Buy |
1,095,357
+313,939
| +40% | +$22.2M | 10.21% | 2 |
|
|
2017
Q1 | $55.6M | Buy |
781,418
+148,226
| +23% | +$10.6M | 9.84% | 2 |
|
|
2016
Q4 | $45.6M | Buy |
+633,192
| New | +$45.6M | 10.25% | 2 |
|